Want to see CH:GALD full AI Analyst Report?
GALD Stock Chart & Stats
CHF173.65
-CHF0.05(-0.03%)
At close: 4:00 PM EDT
CHF173.65
-CHF0.05(-0.03%)
Day’s Range― - ―
52-Week RangeCHF125.10 - CHF188.25
Previous CloseN/A
Volume352.30K
Average Volume (3M)337.59K
Market Cap
CHF41.27B
Enterprise ValueCHF44.67K
Total Cash (Recent Filing)CHF841.26M
Total Debt (Recent Filing)CHF2.70B
Price to Earnings (P/E)53.2
Beta0.80
Next Earnings
Mar 11, 2027EPS Estimate
2.03Next Dividend Ex-DateN/A
Dividend Yield0.2%
Share Statistics
EPS (TTM)4.09
Shares Outstanding237,897,630
10 Day Avg. Volume210,266
30 Day Avg. Volume337,589
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)5.94
Price to Sales (P/S)9.24
P/FCF Ratio46.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF208.83Price Target Upside20.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)4.74
Revenue Forecast (FY)CHF6.37B
Bulls Say, Bears Say
Bulls Say
Profitability TurnaroundHigh gross margins (~67–70%) and improving operating leverage produced a sustained profitability shift, with EBIT margin rising meaningfully by 2025. Durable margin structure supports reinvestment, R&D funding and resilience to cost swings, enhancing long-term cash conversion.
Improved Cash GenerationMaterial free cash flow in 2025 indicates the business can generate cash to fund operations, pay down debt, and support investment without relying on external financing. Strong cash conversion enhances strategic optionality and durability of capital allocation decisions.
Material Leverage ReductionSignificant deleveraging materially lowers financial risk and interest burden, increasing flexibility for M&A, R&D and dividend policy. A stronger capital structure improves resilience to revenue cycles and supports longer-term strategic investments.
Bears Say
Uneven Revenue MomentumA revenue decline in 2025 while margins improved suggests profit gains stemmed from cost/mix rather than consistent top-line growth. Long-term value depends on stable revenue expansion; continued uneven sales risks reversing margin-led earnings improvements.
Large Absolute Debt StockEven with lower leverage ratios, a ~2.75B debt load can constrain strategic flexibility if growth stalls. High absolute debt raises refinancing and interest-rate risk, and could force tighter cash priorities during cyclical downturns or slower revenue periods.
Historical Cash-flow VolatilityThe strong 2025 cash generation follows several years of volatile or negative FCF. This uneven history weakens confidence that recent cash strength is permanent, complicating long-term planning for dividends, buybacks or sustained higher investment levels.
Galderma Group AG News
GALD FAQ
What was Galderma Group AG’s price range in the past 12 months?
Galderma Group AG lowest stock price was CHF125.10 and its highest was CHF188.25 in the past 12 months.
What is Galderma Group AG’s market cap?
Galderma Group AG’s market cap is CHF41.27B.
When is Galderma Group AG’s upcoming earnings report date?
Galderma Group AG’s upcoming earnings report date is Mar 11, 2027 which is in 217 days.
How were Galderma Group AG’s earnings last quarter?
Galderma Group AG released its earnings results on Jul 23, 2026. The company reported CHF1.034 earnings per share for the quarter, missing the consensus estimate of CHF1.441 by -CHF0.407.
Is Galderma Group AG overvalued?
According to Wall Street analysts Galderma Group AG’s price is currently Undervalued.
Does Galderma Group AG pay dividends?
Galderma Group AG pays a Annually dividend of CHF0.35 which represents an annual dividend yield of 0.2%. See more information on Galderma Group AG dividends here
What is Galderma Group AG’s EPS estimate?
Galderma Group AG’s EPS estimate is 2.03.
How many shares outstanding does Galderma Group AG have?
Galderma Group AG has 237,897,630 shares outstanding.
What happened to Galderma Group AG’s price movement after its last earnings report?
Galderma Group AG reported an EPS of CHF1.034 in its last earnings report, missing expectations of CHF1.441. Following the earnings report the stock price went down -2.729%.
Which hedge fund is a major shareholder of Galderma Group AG?
Currently, no hedge funds are holding shares in CH:GALD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
GALD Stock 12 Month Forecast
Average Price Target
CHF208.83
▲(20.26% Upside)